Monitor for additional specialty pharmacy partnerships and any disclosed revenue or prescription volume metrics in future filings. The FemBloc FINALE trial enrollment and regulatory timeline remain the primary catalysts.
Price Chart
Executive Summary
Femasys announced a partnership with SandsRx Pharmacy to support the commercial launch of its FemaSeed fertility treatment and broader portfolio to OB/GYN practices. The agreement is the first in a planned network of specialty pharmacy partnerships, providing medication expertise, education, and preferred pricing. This is a routine commercial expansion step with no disclosed financial terms or revenue impact.
Key Facts
- Femasys entered a partnership with SandsRx Pharmacy, the first in a planned network of specialty pharmacy partnerships.
- The partnership supports the launch of FemaSeed and the broader fertility portfolio to OB/GYN practices.
- SandsRx will provide medication expertise, education, coordinated medication access, and preferred pricing.
- No financial terms, revenue projections, or volume commitments were disclosed.
- Femasys continues to advance FemBloc toward U.S. FDA approval through the FINALE pivotal trial.
Financial Impact
No financial terms disclosed; partnership is operational in nature with no stated revenue or cost impact.
Risk Factors
- Commercial adoption of FemaSeed by OB/GYN practices may be slower than expected.
- No financial terms disclosed, making it difficult to assess materiality.
- Femasys remains pre-revenue or early-revenue; partnership does not change the fundamental cash runway or regulatory risk profile.
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3384450 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 20, 2026 6d ago | Press Release | $1.67 | awaiting T+5 | — | $1.38 (−17.37%) |
Oct 15, 2026 11d ago | SC 13G | $1.74 $1.56 | ▼ −10.09% | ▼ −9.07% | $1.38 (−20.46%) |
Sep 29, 2026 27d ago | EFFECT | $2.09 $2.08 | ▲ +0.48% | ▲ +2.43% | $1.38 (+33.97%) |
Aug 14, 2026 10w ago | 8-K | $2.16 $2.98 | ▼ −37.96% | ▼ −39.15% | $1.38 (+36.11%) |
Aug 14, 2026 10w ago | Press Release | $2.16 $2.98 | ▲ +37.96% | ▲ +39.15% | $1.38 (−36.11%) |
Aug 11, 2026 10w ago | Insider Cluster | $2.35 $2.71 | ▲ +15.32% | ▲ +15.76% | $1.38 (−41.28%) |
Aug 7, 2026 11w ago | Press Release | $2.66 $2.29 | ▲ +13.91% | ▲ +14.31% | $1.38 (+48.12%) |
Jun 4, 2026 20w ago | 8-K | $7.14 $4.78 | ▼ −33.05% | ▼ −30.50% | $1.38 (−80.67%) |
May 13, 2026 23w ago | 8-K | $7.61 $6.75 | ▼ −11.38% | ▼ −10.66% | $1.38 (−81.87%) |
May 8, 2026 24w ago | 8-K | $8.08 $7.26 | ▼ −10.24% | ▼ −10.16% | $1.38 (−82.93%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers